In conclusion, our findings support a paradigm in which regulatory ISGs limit the optimal anti-tumor effectiveness of immunotherapies implementing STING agonists such as ADU-S100, with the operationally relevant regulatory ISGs varying in a melanoma model-dependent manner which could have implications for heterogeneous responses in melanoma patients to STING agonists in the clinic. This evidence concerns the gene STING1 and melanoma.